Skip to main content
Clinical Trials/NCT06620016
NCT06620016
Recruiting
Not Applicable

Diagnostic Role of Circulating microRNAs in Small Testicular Masses Suitable for Testis Sparing Surgery and Post-chemotherapy Residual Masses Suitable for Retroperitoneal Lymph Node Dissection.

IRCCS Azienda Ospedaliero-Universitaria di Bologna1 site in 1 country60 target enrollmentOctober 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Testicular Cancer
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
60
Locations
1
Primary Endpoint
MicroRNA's germ cell cancer detection (Cohort A)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to evaluate the diagnostic performance of circulating microRNAs in detecting the presence of germ cell cancer in patients with small testicular mass or retroperitoneal post-chemotherapy residual mass and suitable for testis sparing surgery and retroperitoneal lymph node dissection, respectively.

Registry
clinicaltrials.gov
Start Date
October 1, 2024
End Date
October 31, 2027
Last Updated
last year
Study Type
Observational
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \>= 18 years
  • Single testicular lesion, with \< 2 cm diameter and \< 30 % testicular volume involvement;
  • Negative Serum Tumour Markers;
  • Suitable for testis sparing surgery;
  • Informed consent.

Exclusion Criteria

  • Inclusion Criteria:
  • Age \>= 18 years
  • Single/multiple post-chemotherapy retroperitoneal lymph node lesion, with \> 1 cm (non seminomatous) / \> 3 cm (seminomatous) diameter in patients with previous testicular germ cell primary tumour;
  • Negative Serum Tumour Markers;
  • Suitable for retroperitoneal lymph node dissection;
  • Informed consent.
  • Exclusion Criteria:

Outcomes

Primary Outcomes

MicroRNA's germ cell cancer detection (Cohort A)

Time Frame: Baseline.

Preoperative circulating microRNA's diagnostic accuracy in detecting germ cell cancer in patients with small testicular mass and submitted to testis sparing surgery, using post-operative surgical specimen as reference.

MicroRNA's germ cell cancer detection (Cohort B)

Time Frame: Baseline.

Preoperative circulating microRNA's diagnostic accuracy in detecting germ cell cancer in patients with post-chemotherapy residual mass and submitted to retroperitoneal lymph node dissection, using post-operative surgical specimen as reference.

Secondary Outcomes

  • MicroRNA's germ cell cancer subtype detection (Cohort A + B)(Baseline.)
  • MicroRNA's vs Frozen Section Examination's germ cell cancer detection (Cohort A)(Baseline.)
  • MicroRNA's disease recurrence/persistence detection (Cohort A + B)(Week 4.)

Study Sites (1)

Loading locations...

Similar Trials